Fair comments TT. I of course cannot assume something went wrong with the test, however 2 things which have already been raised by others.
1. If the test was conducted in the same manner, why such a difference in results?
2. If it is purely due to different strains (which we also don’t know for sure, is part speculation on our part as well), then we assume the company hasn’t been up to date with the covid algorithm since the initial results? This then points to negligence, especially as they’ve baked it to the revised scheme offer.
You would be bold to make investment decisions based on speculation the delta and omicron variants (may) have had such impacts on the result, I wouldn’t beat yourself up too much for that.
RAP Price at posting:
13.0¢ Sentiment: Buy Disclosure: Held
(20min delay)